Hepatitis Monthly

Published by: Kowsar

The ITPA and C20orf194 Polymorphisms and Hematological Changes During Treatment With Pegylated-Interferon Plus Ribavirin in Patients With Chronic Hepatitis C

Mohammad Pouryasin 1 , 2 , 3 , Maryam Keshvari 4 , Heidar Sharafi 1 , 2 , 5 , Seyed Moayed Alavian 1 , 5 , Bita Behnava 1 , 5 , Seyed Ehsan Alavian 1 , 5 and Ali Pouryasin 2 , 6 , *
Authors Information
1 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
2 Armin Pathobiology Laboratory, Tehran, IR Iran
3 Department of Biology, Tabriz Branch, Islamic Azad University, Tabriz, IR Iran
4 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, IR Iran
5 Middle East Liver Diseases (MELD) Center, Tehran, IR Iran
6 Department of Biology, Arsanjan Branch, Islamic Azad University, Arsanjan, IR Iran
Article information
  • Hepatitis Monthly: March 01, 2016, 16 (2); e35278
  • Published Online: March 20, 2016
  • Article Type: Research Article
  • Received: December 8, 2015
  • Accepted: December 9, 2015
  • DOI: 10.5812/hepatmon.35278

To Cite: Pouryasin M, Keshvari M, Sharafi H, Alavian S M, Behnava B, et al. The ITPA and C20orf194 Polymorphisms and Hematological Changes During Treatment With Pegylated-Interferon Plus Ribavirin in Patients With Chronic Hepatitis C, Hepat Mon. 2016 ; 16(2):e35278. doi: 10.5812/hepatmon.35278.

Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Hepatitis C. Geneva; WHO. 2015;
  • 2. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002; 36(5 Suppl 1)-9[DOI][PubMed]
  • 3. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002; 36(5 Suppl 1)-46[DOI][PubMed]
  • 4. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347(13): 975-82[DOI][PubMed]
  • 5. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358(9286): 958-65[PubMed]
  • 6. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009; 361(6): 580-93[DOI][PubMed]
  • 7. Rau M, Baur K, Geier A. Host genetic variants in the pathogenesis of hepatitis C. Viruses. 2012; 4(12): 3281-302[PubMed]
  • 8. Rembeck K, Waldenstrom J, Hellstrand K, Nilsson S, Nystrom K, Martner A, et al. Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. Hepatology. 2014; 59(6): 2131-9[DOI][PubMed]
  • 9. Thompson AJ, Clark PJ, Singh A, Ge D, Fellay J, Zhu M, et al. Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol. 2012; 56(2): 313-9[DOI][PubMed]
  • 10. Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 2010; 464(7287): 405-8[DOI][PubMed]
  • 11. Thompson AJ, Santoro R, Piazzolla V, Clark PJ, Naggie S, Tillmann HL, et al. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology. 2011; 53(2): 389-95[DOI][PubMed]
  • 12. Thompson AJ, Fellay J, Patel K, Tillmann HL, Naggie S, Ge D, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology. 2010; 139(4): 1181-9[DOI][PubMed]
  • 13. Hitomi Y, Cirulli ET, Fellay J, McHutchison JG, Thompson AJ, Gumbs CE, et al. Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. Gastroenterology. 2011; 140(4): 1314-21[DOI][PubMed]
  • 14. Furusyo N, Katoh M, Tanabe Y, Kajiwara E, Maruyama T, Shimono J, et al. Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: a project of the Kyushu University Liver Disease Study Group. World J Gastroenterol. 2006; 12(5): 784-90[PubMed]
  • 15. Krishnan SM, Dixit NM. Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy. PLoS Comput Biol. 2011; 7(2)[DOI][PubMed]
  • 16. Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Kubo M, et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients. Gastroenterology. 2010; 139(4): 1190-7[DOI][PubMed]
  • 17. Delvaux N, Costa VD, Costa MM, Villar LM, Coelho HS, Esberard EB, et al. Inosine triphosphatase allele frequency and association with ribavirin-induced anaemia in Brazilian patients receiving antiviral therapy for chronic hepatitis C. Mem Inst Oswaldo Cruz. 2015; 110(5): 636-43[DOI][PubMed]
  • 18. Haj-Sheykholeslami A, Keshvari M, Sharafi H, Pouryasin A, Hemmati K, Mohammadzadehparjikolaei F. Interferon-lambda polymorphisms and response to pegylated interferon in Iranian hepatitis C patients. World J Gastroenterol. 2015; 21(29): 8935-42[DOI][PubMed]
  • 19. Sharafi H, Alavian SM, Behnava B, Pouryasin A, Keshvari M. The Impact of IFNL4 rs12979860 Polymorphism on Spontaneous Clearance of Hepatitis C; A Case-Control Study. Hepat Mon. 2014; 14(10)[DOI][PubMed]
  • 20. Keshvari M, Pouryasin A, Behnava B, Sharafi H, Hajarizadeh B, Alavian SM. Letter: the rs12979860 and ss469415590 polymorphisms of IFNL4 gene are in strong linkage disequilibrium in Caucasian patients with chronic hepatitis C. Aliment Pharmacol Ther. 2014; 39(3): 343[DOI][PubMed]
  • 21. Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Salimi S, et al. Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals. Hepat Mon. 2012; 12(12)[DOI][PubMed]
  • 22. Sharafi H, Alavian SM. IL28B polymorphism, Explanation for Different Responses to Therapy in Hepatitis C Patients. Hepat Mon. 2011; 11(12): 958-9[DOI][PubMed]
  • 23. Ahmed WH, Furusyo N, Zaky S, Eldin AS, Aboalam H, Ogawa E, et al. Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients. World J Gastroenterol. 2013; 19(9): 1387-95[DOI][PubMed]
  • 24. Naggie S, Rallon NI, Benito JM, Morello J, Rodriguez-Novoa S, Clark PJ, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes. J Infect Dis. 2012; 205(3): 376-83[DOI][PubMed]
  • 25. D'Avolio A, De Nicolo A, Cusato J, Ciancio A, Boglione L, Strona S, et al. Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. Antiviral Res. 2013; 100(1): 114-9[DOI][PubMed]
  • 26. Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis. 1999; 19 Suppl 1: 67-75[PubMed]
  • 27. McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis. 1999; 19 Suppl 1: 57-65[PubMed]
  • 28. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology. 2003; 124(6): 1711-9[PubMed]
  • 29. Takaki S, Tsubota A, Hosaka T, Akuta N, Someya T, Kobayashi M, et al. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol. 2004; 39(7): 668-73[DOI][PubMed]
  • 30. Nomura H, Tanimoto H, Kajiwara E, Shimono J, Maruyama T, Yamashita N, et al. Factors contributing to ribavirin-induced anemia. J Gastroenterol Hepatol. 2004; 19(11): 1312-7[DOI][PubMed]
  • 31. Scherzer TM, Stattermayer AF, Stauber R, Maieron A, Strasser M, Laferl H, et al. Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients. J Hepatol. 2013; 59(5): 964-71[DOI][PubMed]
  • 32. Van Vlierbergh H, Delanghe JR, De Vos M, Leroux-Roel G, Basl Steering Committee. . Factors influencing ribavirin-induced hemolysis. J Hepatol. 2001; 34(6): 911-6[PubMed]
  • 33. Lindahl K, Schvarcz R, Bruchfeld A, Stahle L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepat. 2004; 11(1): 84-7[PubMed]
  • 34. Pineda-Tenor D, Garcia-Alvarez M, Jimenez-Sousa MA, Vazquez-Moron S, Resino S. Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis. J Transl Med. 2015; 13: 320[DOI][PubMed]
  • 35. Sumi S, Marinaki AM, Arenas M, Fairbanks L, Shobowale-Bakre M, Rees DC, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet. 2002; 111(4-5): 360-7[DOI][PubMed]
  • 36. Cao H, Hegele RA. DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency. J Hum Genet. 2002; 47(11): 620-2[DOI][PubMed]
  • 37. Arenas M, Duley J, Sumi S, Sanderson J, Marinaki A. The ITPA c.94C>A and g.IVS2+21A>C sequence variants contribute to missplicing of the ITPA gene. Biochim Biophys Acta. 2007; 1772(1): 96-102[DOI][PubMed]
  • 38. Stepchenkova EI, Tarakhovskaya ER, Spitler K, Frahm C, Menezes MR, Simone PD, et al. Functional study of the P32T ITPA variant associated with drug sensitivity in humans. J Mol Biol. 2009; 392(3): 602-13[DOI][PubMed]
  • 39. Chen SH, Peng CY, Lai HC, Su WP, Lin CH, Li YF, et al. An index to predict ribavirin-induced anemia in asian patients with chronic genotype 1 hepatitis C. Hepat Mon. 2015; 15(3)[DOI][PubMed]
  • 40. Fujino T, Aoyagi Y, Takahashi M, Yada R, Yamamoto N, Ohishi Y, et al. Association of ITPA polymorphism with outcomes of peginterferon-alpha plus ribavirin combination therapy. World J Gastrointest Pharmacol Ther. 2013; 4(3): 54-60[DOI][PubMed]
  • 41. Maan R, van der Meer AJ, Brouwer WP, Plompen EP, Sonneveld MJ, Roomer R, et al. ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection. PLoS One. 2015; 10(10)[DOI][PubMed]
  • 42. Broudy VC, Lin NL, Kaushansky K. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood. 1995; 85(7): 1719-26[PubMed]
  • 43. Cardier JE, Erickson-Miller CL, Murphy MJ , Jr.. Differential effect of erythropoietin and GM-CSF on megakaryocytopoiesis from primitive bone marrow cells in serum-free conditions. Stem Cells. 1997; 15(4): 286-90[DOI][PubMed]
  • 44. Kobayashi T, Hige S, Terashita K, Nakai M, Horimoto H, Sho T, et al. Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C. J Gastroenterol. 2012; 47(11): 1228-37[DOI][PubMed]
  • 45. Tseng KC, Chen LH, Chen CY, Chang TT, Chou AL, Wu IC, et al. Low dose erythropoietin-beta improves anemia and maintains ribavirin dose in chronic hepatitis C patients receiving combination therapy with ribavirin plus pegylated interferon Alfa-2b. Hepatol Res. 2009; 39(6): 539-45[DOI][PubMed]
  • 46. Bilic E, Bilic E. Amino acid sequence homology of thrombopoietin and erythropoietin may explain thrombocytosis in children with iron deficiency anemia. J Pediatr Hematol Oncol. 2003; 25(8): 675-6[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments